[1]
A. Almaaytah and F. D. Elhajji, “Comparative Cost Efficiency of the Originator Drug of Infliximab and its Biosimilar for the Treatment of Rheumatoid Arthritis in the MENA Region”, ijpi, vol. 9, no. 1, pp. 12-15, Mar. 2019.